GR only rehashed known information and utilized too much "promising," not giving the investor any significant confidence with a biotech. Furthermore, he used a rookie IPO ploy of "1% of marketshare" to beef up confidence, weak. He should have set a more concrete pathway for investors; however, he made the company seem too infant and not as mature as I would have hoped.
I don't see this stock moving to a .2 bottom level until Q4 '13. GR should have said a few words and given the mic to Lanza. Not that I do not believe this stock will improve, but it's not moving for another 10 - 12 months. I wouldn't waste your money on a .08 - .09 buy, just wait unit .06 and make your money off of the in-and-out rookies who beef the stock up to .09 every few months.
I agree it is 2013 and if we are half way there the market is always a forward looking tool so i think by summer you will see this stock pick up some steam and by winter it will be to late to buy it cheap.
"known information" ... To whom? This was for NEW investors and people interested in stem cell research. Hence, the elementary education at the beginning. He had 30 minutes to get their attention, not cover a-z of Actc.